You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

MustGrow Biologics Corp - Ordinary Shares (MGRO)
- P/E (TTM): -31.3X Cap: $140M
- View MGRO Profile
- View Questions on MGRO

Q: Thoughts please on this bio-tech news release.
MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter

Asked by Tim on August 28, 2025

5i Research Answer:

MGRO had a loss of 2c per share in the second quarter, matching estimates. Revenue of $2.8M missed estimates of $5.2M. Keep in mind there is only one analyst on the company, and its very small size means volatility will be commonplace. It had no sales in the prior year period. Gross margin increased 6.6 points, and cash was $1.8M. Sales of Terra Sante tripled from last year, which is positive. Still, losses continue and cash flow has been negative for the past eight years. The stock is down 36% and its small size and risk makes it hard for us to endorse it.

Let us help YOU reach your financial goals today!

Start your FREE trial today and enjoy all the benefits of a 5i Membership including:

Access to a team of experts ready to answer your investments question
Instant access to over 100,000 archived questions
A community of like-minded investors
Peace of mind knowing that 5i Research has only YOUR best interests in mind

First Name *

Last Name *

E-mail *

Password *

I have read and agree to the Terms of Use